Ardelyx (ARDX) said Thursday that it expects 2026 revenue of between $410 million and $430 million for Ibsrela, its drug to treat chronic idiopathic constipation.
The biopharmaceutical company also said it expects 2026 revenue of between $110 million and $120 million for Xphozah, which reduces serum phosphorus in adults with chronic kidney disease.
Shares of Ardelyx were up 4.6% pre-bell.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments